NCT04325490 is a Phase 4 clinical trial of Liquid powder in Intertrigo, sponsored by Mahidol University.

Who is sponsoring NCT04325490?

NCT04325490 is sponsored by Mahidol University.

What drugs are being tested in NCT04325490?

Interventions in NCT04325490: Liquid powder, Hydrocortisone cream 1%.

What condition does NCT04325490 study?

NCT04325490 studies Intertrigo.

Is NCT04325490 still recruiting?

NCT04325490 is currently completed. Last updated 20 April 2021.

Last reviewed 2021-04-20 · How we verify

NCT04325490

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tapioca Starch Stimutex AS, Aloe Barbadensis, Rose Hip Oil, Allantoin Comparing With Topical 1% Hydrocortisone Cream

Completed Phase 4 Last updated 20 April 2021

What this trial tests

Phase 4 trial testing Liquid powder in Intertrigo in 40 participants. Completed in 30 September 2020.

Timeline

1 October 2019

Primary endpoint
30 September 2020

30 September 2020

Quick facts

Lead sponsor	Mahidol University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	40
Start date	1 October 2019
Primary completion	30 September 2020
Estimated completion	30 September 2020
Sites	1 location across Thailand

Drugs / interventions tested

Liquid powder
Hydrocortisone cream 1%

Conditions studied

Intertrigo — all drugs for Intertrigo →

Sponsor

Mahidol University

Who can join

18 and older, any sex, with Intertrigo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized controlled trial of efficiency and safety of liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin comparing with topical 1% hydrocortisone cream for the treatment of intertrigo

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mahidol University trials

Trials by the same sponsor.

NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04325490 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahidol University
Last refreshed: 20 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04325490.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing